Researchers from North Carolina State University have synthesized an analog of lipoxazolidinone A, a small molecule that is effective against drug-resistant bacteria such as MRSA. This molecule, a new synthetic compound inspired by a natural product, could be a useful chemical tool for studying other Gram-positive infections and may have implications for future drug creation.
Lipoxazolidinone A is a natural product which had been previously isolated from bacteria living in marine sediments. It is a secondary metabolite – a small molecule produced by the bacteria that isn’t key to its survival but is produced for a secondary purpose, like defense. When lipoxazolidinone A was initially isolated, researchers noted that it seemed effective against Gram-positive bacteria, like MRSA.
NC State chemist Joshua Pierce aimed to confirm those original findings and understand how the molecule’s structure correlated to its function; in short, he wanted to recreate the molecule to see what portions were directly responsible for its anti-microbial properties and then potentially improve upon that structure.
Pierce, along with current NC State graduate student Kaylib Robinson and former students Jonathan Mills and Troy Zehnder, used novel chemical tools to synthesize lipoxazolidinone A in the lab. They were able to confirm that its chemical structure matched what the initial researchers had indicated, then they worked to identify the portion of the molecule that was responsible for the activity against Gram-positive bacteria. Their result was a compound with improved potency, JJM-35.
They tested JJM-35 against a panel of resistant and non-resistant bacteria. When tested against MRSA in vitro, they found that the synthesized molecule was up to 50 times more effective than the natural product against several bacterial strains. Additionally, they found that the molecule was often more effective against resistant bacterial strains than it was against nonresistant strains.
“An exciting additional aspect of this work was that we identified that these molecules may function by inhibiting multiple biosynthetic pathways directly or indirectly,” says Pierce. “This means that bacteria may have difficulty developing resistance to potential drugs developed from these molecules.”
While more work is needed, Pierce hopes that JJM-35 and similar compounds can be used as tools to study other Gram-positive bacteria and provide a platform for the development of a novel class of anti-infective agents.
“At this point, we have a chemical scaffold – a starting piece of the puzzle. We know that this piece is effective, and so right now all efforts are focused on evaluating the properties of these molecules and their in vivo efficacy,” says Pierce. “The hope is that we can build upon this scaffold to create drugs that are effective against MRSA and other resistant bacteria at a time of dire need for antimicrobial development while also increasing the spectrum of activity.”
Receive an email update when we add a new ANTIMICROBIAL RESISTANCE article.
The Latest on: Antimicrobial development
via Google News
The Latest on: Antimicrobial development
- Antimicrobial Use and Antimicrobial Resistance FAQ on December 9, 2018 at 4:37 am
Veterinarians are concerned about the development of antimicrobial resistance in organisms that infect animals because it may compromise the effectiveness of antimicrobial therapy for animal diseases ... […]
- Opinion: It takes a coalition to defeat antimicrobial resistance on December 6, 2018 at 12:24 pm
Get development's most important headlines in your inbox every ... In Jordan, we mobilized a multidisciplinary group of stakeholders from three hospitals that implemented an antimicrobial stewardship ... […]
- Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract Infections on December 6, 2018 at 6:00 am
As a unit within GSK's research and development organization ... Fimbrion's mission is to discover, develop, and commercialize antimicrobial-sparing, first-in-class anti-virulence drugs for the preven... […]
- 5 key strategies to mitigate the effect of antimicrobial resistance on December 5, 2018 at 3:22 pm
"Antimicrobial resistance is as much a part of our world ... In recent years, there has been a major reduction in the pipeline for the development of new antibiotics, which means there won't be many n... […]
- GeneFluidics Selected as One of Five Finalists for Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2 on December 5, 2018 at 10:03 am
The main purpose of the Antimicrobial Resistance Rapid Challenge is to incentivize the development of in vitro diagnostic tests that would be of significant clinical and public health utility to comba... […]
- Study: Listeria and Antimicrobial Resistance on December 5, 2018 at 7:30 am
The research paper is entitled, “Modelling the microbial dynamics and antimicrobial resistance development of Listeria in viscoelastic food model systems of various structural complexities”. The study ... […]
- ‘Antimicrobial Resistance Knows No Boundaries’ on December 4, 2018 at 8:21 am
Antimicrobial resistance (AMR ... An Organisation for Economic Co-operation and Development (OECD) study showed that while AMR rates averaged 17 percent in OECD countries in 2015, rates in India, Chin... […]
- Global Antimicrobial Coating Market 2018-2025, Axalta Coating Systems, AkzoNobel, BASF, PPG Industries, RPM International on December 2, 2018 at 10:45 pm
practicableness of investment study, Antimicrobial Coating market standing from 2013 to 2018, Antimicrobial Coating business development trends from 2018 to 2025 and rising market segments can outline ... […]
- Statement re ECO Animal Health and Agrinnovation (Yissum) L.P. sign swine antimicrobial novel formulation development and licencing deal on December 2, 2018 at 10:00 pm
ECO Animal Health and Agrinnovation (Yissum) L.P. sign swine antimicrobial novel formulation development and licencing deal ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health ... […]
via Bing News